MMED (Minimed Group) 3-Year EBITDA Growth Rate: 0.00% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MMED Minimed Group Inc MMED
15 GF Score
Price $19.85
! 3 Warning Signs
View Full Analysis

What is Minimed Group 3-Year EBITDA Growth Rate?

Minimed Group MMED +1.77% 15 3-Year EBITDA Growth Rate is 0.00% as of Apr. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Minimed Group ranks worse than 144927.39% on this metric.

Minimed Group's EBITDA per Share for the three months ended in Apr. 2026 was $-0.17.

During the past 12 months, Minimed Group's average EBITDA Per Share Growth Rate was -101.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Minimed Group  (NAS:MMED) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Minimed Group 3-Year EBITDA Growth Rate Related Terms

MMED vs MMSI, NVST, STVN: 3-Year EBITDA Growth Rate Comparison

For the Medical Instruments & Supplies subindustry, Minimed Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minimed Group 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Minimed Group's 3-Year EBITDA Growth Rate falls into.


MMED
15GF Score
Minimed Group Inc MMED
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Minimed Group (MMED) has a 3-Year EBITDA Growth Rate of 0.00% as of Apr. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Minimed Group and its competitors. According to the industry distribution chart, Minimed Group ranks #999999 out of 690 companies in the Medical Devices & Instruments industry.
Is Minimed Group's 3-Year EBITDA Growth Rate too high?
Minimed Group's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Minimed Group ranks #999999 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's 3-Year EBITDA Growth Rate compare to MMSI and NVST?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #999999 out of 690 companies for 3-Year EBITDA Growth Rate. This places Minimed Group in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Minimed Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Minimed Group's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Minimed Group (MMED), the current 3-Year EBITDA Growth Rate is 0.00% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges B8S:Germany
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for MMED

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.85
Price